At AHA 2024, the safety of GLP-1R agonists in heart failure and chronic kidney disease (CKD) patients was discussed.

New data from Barinthus Bio's HBV003 trial has demonstrated durable HBsAG loss in participants with chronic hepatitis B.

The discussion at AHA emphasised that the FLOW trial established that semaglutide prevents major kidney outcomes and major ...

The ASI drug class potentially fills an unmet need in the CKD space. Credit: crystal light via Shutterstock. On 15 November ...

The topline results found that the TenNor rifasutenizol trial showed better safety and tolerability than the current standard ...

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...

The failure of the Eyenovia CHAPERONE study has seen the company’s stock value drop drastically as it weighs up options and ...

GlobalData forecasts that the prostate cancer market is set to increase by 25% from $475.84 million in 2024 to $596.22 ...

Atrial flutter is a type of abnormal heart rhythm that causes rapid and irregular beating of the upper chambers of the heart. Credit: Rawpixel.com via Shutterstock. Intellia Therapeutics has announced ...

The trial evaluated nucresiran’s safety, pharmacokinetics and pharmacodynamics in healthy individuals. Credit: Andrei_R/Shutterstock. Alnylam Pharmaceuticals has revealed new interim data from its ...

The study involved 731 participants who were randomised to receive either tirzepatide or placebo. Credit: Africa Studio/Shutterstock. Eli Lilly has reported comprehensive outcomes from the Phase III ...